BioSpace News Archive

Hemostemix Engages Montreal’s RobboDesign to SEO Its Website to Engage with 236 Million Peripheral Arterial Disease and Critical Limb Ischemia Patients Globally

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce it has engaged Montreal’s RobboDesign to revise and search engine optimize its website, to engage with critical limb ischemia “CLI” and peripheral arterial disease “PAD” patients, globally.

March 29, 2023
·
8 min read
Drug Development

Bolt Biotherapeutics Announces Positive Topline Data from BDC-1001 Phase 1 Dose-Escalation Trial in HER2-Expressing Tumors, Supporting Advancement to Phase 2 Clinical Studies

Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) today reported positive topline data from the company’s recently completed dose-escalation study of BDC-1001 in HER2-expressing solid tumors that support advancing into two Phase 2 studies.

March 29, 2023
·
9 min read
Business

Journey Medical Corporation Reports Full-Year 2022 Financial Results and Recent Corporate Highlights

Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) today announced financial results and recent corporate highlights for the fourth quarter and full year ended December 31, 2022.

March 29, 2023
·
17 min read
Business

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth quarter and full year 2022 financial results on Monday, April 3, 2023.

March 29, 2023
·
1 min read
Drug Development

Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced a positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) as well as details of the anticipated SYNCHRONY Phase 3 efruxifermin program for the treatment of nonalcoholic steatohepatitis (NASH).

March 29, 2023
·
7 min read
Business

Arcellx Provides Fourth Quarter and Year-End 2022 Financial Results and Business Highlights

Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2022.

March 29, 2023
·
9 min read
Business

AN2 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today reported financial results for the fourth quarter and year ended December 31, 2022.

March 29, 2023
·
10 min read
Business

Evolent Health and Centene Agree to Expanded Partnership for Oncology Specialty Care for Medicare Advantage Members

Evolent Health, Inc., a health care company that delivers proven value-based specialty care solutions to payers and providers, announced an agreement to expand its Technology and Services solution for oncology with its existing partner, Centene Corporation,.

March 29, 2023
·
2 min read
Business

Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 30

Avadel Pharmaceuticals plc announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 30, 2023, to provide a corporate update and discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2022.

March 29, 2023
·
1 min read
Business

bluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today reported financial results and business highlight.

March 29, 2023
·
13 min read